Kevzara FDA Approval History
Last updated by Judith Stewart, BPharm on April 8, 2020.
FDA Approved: Yes (First approved May 22, 2017)
Brand name: Kevzara
Generic name: sarilumab
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: Rheumatoid Arthritis
Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).Kevzara is also being evaluated in a global clinical trial program as a potential treatment for patients who are hospitalized with COVID-19. Scientists have preliminary evidence that IL-6 may play a key role in driving the inflammatory immune response that causes acute respiratory distress syndrome (ARDS) in critically ill COVID-19 patients.
Development Timeline for Kevzara
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.